Codon-Optimized MeCP2 Expression for Rett Syndrome Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating Rett syndrome, a neurodevelopmental disorder caused by loss of function of the MeCP2 protein, are ineffective in improving neurological outcomes, and existing attempts to express MeCP2 proteins have been unsuccessful in producing sufficient amounts for therapeutic purposes.
Innovation Solution
The development of codon-optimized nucleic acid sequences for expressing biologically active MeCP2 proteins, fused with protein transduction domains like TAT, to enable their entry into nervous system cells and compensate for MeCP2 deficiency, using optimized expression systems like E. coli to enhance protein production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional nucleic acid sequences are used to express MeCP2 protein, then the sequence can be synthesized and introduced into expression systems, but the protein yield is insufficient for therapeutic purposes
Solution Approach 1:
The patent applies codon optimization to change the nucleic acid sequence parameters while maintaining the same amino acid sequence. By optimizing codon usage frequency and GC content, the expression efficiency of MeCP2 protein is significantly improved, achieving sufficient protein yield for therapeutic purposes without altering the protein's primary structure or function.
2Reliability
If gene therapy approaches are used to deliver MeCP2, then MeCP2 expression can be restored, but insertional mutagenesis and immunological reactions occur
Solution Approach 1:
The patent extracts the MeCP2 coding sequence from its native genomic context and expresses it as a standalone recombinant protein in bacterial systems. This eliminates the risks of insertional mutagenesis and immunological reactions associated with gene therapy approaches, while still achieving restoration of MeCP2 function through protein replacement.
Solution Approach 2:
The patent uses bacterial expression systems as intermediaries to produce human MeCP2 protein. The bacteria serve as a safe intermediary platform that can be precisely controlled, allowing production of therapeutic protein without direct genetic modification of patient cells, thereby avoiding insertional mutagenesis and reducing immunogenicity.
3Reliability
If protein substitution therapy is implemented, then MeCP2 deficiency can be compensated, but sufficient biologically active protein must be produced
Solution Approach 1:
The patent optimizes nucleic acid sequence parameters including codon usage frequency and GC content to maximize protein expression levels. These parameter changes enable the production of sufficient biologically active MeCP2 protein in bacterial systems, ensuring effective compensation for MeCP2 deficiency while maintaining protein functionality.
Data Source
Figure 1A~1C
Figure 2
Figure 3A~3D
AI summary
The invention relates to the MeCP2 protein and its use in protein substitution therapy. More specifically, the invention relates to codon-optimized nucleic acid sequences for the expression of MeCP2 proteins, methods for creating such a nucleic acid sequence and expressing such a protein, fusions of a protein of the invention to a transduction domain, and vectors and host cells comprising a protein of the invention. Further, the invention relates to uses of nucleic acids or proteins of the invention in medicine, pharmaceutical compositions comprising nucleic acid sequences and proteins of the invention, as well as methods for the treatment, prevention, and/or therapy of neurodegenerative or neurodevelopmental diseases including Rett syndrome.